You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,918,950

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,918,950

Title:	Targeted treatment of anerobic cancer
Abstract:	The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor\'s metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy.
Inventor(s):	Haaga; John R. (Chagrin Falls, OH), Haaga; Rebecca (Chagrin Falls, OH)
Assignee:	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (Cleveland, OH)
Application Number:	15/229,720
Patent Claims:	1. A method for treating a patient with cancer, said method comprising: a) providing: i) a patient exhibiting a neoplasm, wherein said neoplasm comprises a plurality of blood vessels; and ii) a composition comprising at least one polymer and bumetanide; b) administering said composition to said patient under conditions such that said blood vessels are occluded, wherein said blood vessel occlusions comprises emboli. 2. The method according to claim 1, wherein said neoplasm is hypoxic. 3. The method according to claim 1, wherein said administering results in the shrinkage of said neoplasm. 4. The method according to claim 1, wherein said administering further comprises an angiogenesis inhibitor. 5. The method according to claim 4, wherein said angiogenesis inhibitor is selected from the group consisting of ZD6474, ZD 6126, AZD2171, SU6668, SU5416, bevacizumab, mv833, anti-FLT-1 ribozyme, SU5416, PTK 787, ZD4190, ZD6474, CEP-7055, SU11248, and mixtures thereof. 6. The method according to claim 1, wherein said emboli comprises said composition. 7. The method according to claim 6, wherein said administering of said composition is repeated. 8. The method according to claim 6, wherein said composition comprises a slow-release polymer formulation. 9. The method according to claim 1, wherein said administering further comprises a thermal ablation of said neoplasm. 10. The method according to claim 9, wherein said thermal ablation is preceded by said bumetanide composition administration. 11. The method according to claim 9, wherein said thermal ablation comprises radiofrequency thermal ablation. 12. The method according to claim 9, wherein said thermal ablation comprises cryoablation. 13. The method according to claim 9, wherein said thermal ablation comprises microwave ablation. 14. The method according to claim 9, wherein said thermal ablation comprises laser ablation. 15. The method according to claim 9, wherein said thermal ablation comprises ultrasound ablation.

Details for Patent 9,918,950

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.